These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 31612807)

  • 1. Managing Side Effects on Ocular Surface Caused by Glaucoma Eye Drops.
    Ferreras A; Figus M; Fogagnolo P; Iester M; Frezzotti P
    Curr Med Chem; 2019; 26(22):4223-4224. PubMed ID: 31612807
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis.
    Hedengran A; Steensberg AT; Virgili G; Azuara-Blanco A; Kolko M
    Br J Ophthalmol; 2020 Nov; 104(11):1512-1518. PubMed ID: 32051133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease.
    Goldberg I; Graham SL; Crowston JG; d'Mellow G;
    Clin Exp Ophthalmol; 2015 Apr; 43(3):214-20. PubMed ID: 25196488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives.
    Ramli N; Supramaniam G; Samsudin A; Juana A; Zahari M; Choo MM
    Optom Vis Sci; 2015 Sep; 92(9):e222-6. PubMed ID: 25730335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preservatives in glaucoma medication.
    Steven DW; Alaghband P; Lim KS
    Br J Ophthalmol; 2018 Nov; 102(11):1497-1503. PubMed ID: 29973365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conjunctival Goblet Cells, the Overlooked Cells in Glaucoma Treatment.
    Tiedemann D; Mouhammad ZA; Utheim TP; Dartt DA; Heegaard S; Petrovski G; Kolko M
    J Glaucoma; 2019 Apr; 28(4):325-333. PubMed ID: 30585937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Corneal epithelium and limbal region alterations due to glaucoma medications evaluated by anterior segment optic coherence tomography: a case-control study.
    Güçlü H; Çınar AK; Çınar AC; Akaray İ; Şambel Aykutlu M; Sakallıoğlu AK; Gürlü V
    Cutan Ocul Toxicol; 2021 Jun; 40(2):85-94. PubMed ID: 33719786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tear Film Osmolarity, Ocular Surface Disease and Glaucoma: A Review.
    Fogagnolo P; Torregrossa G; Tranchina L; Ferreras A; De Cillá S; Labbé A; Figus M; Ottobelli L; Rossetti L
    Curr Med Chem; 2019; 26(22):4241-4252. PubMed ID: 31345142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular benzalkonium chloride exposure: problems and solutions.
    Goldstein MH; Silva FQ; Blender N; Tran T; Vantipalli S
    Eye (Lond); 2022 Feb; 36(2):361-368. PubMed ID: 34262161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prescription trends for preservative free glaucoma medication in a public health system.
    Pérez-García P; Burgos-Blasco B; Morales-Fernández L; Fernández-Ruiz-Morón A; Gómez-Calleja V; Oribio-Quinto C; Collado-Vincueria I; Garcia-Feijoo J; Martinez-de-la-Casa JM
    Eur J Ophthalmol; 2024 Jan; 34(1):193-203. PubMed ID: 37070183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study.
    Aihara M; Oshima H; Araie M;
    Acta Ophthalmol; 2013 Feb; 91(1):e7-e14. PubMed ID: 23241328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effects of Latanoprost With Benzalkonium Chloride Versus Travoprost With SofZia on the Ocular Surface.
    Rahmatnejad K; Rapuano CJ; Ichhpujani P; Wizov SS; Moster MR; Hark LA; Katz LJ
    Eye Contact Lens; 2018 Nov; 44 Suppl 2():S93-S98. PubMed ID: 28617732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-Reported Nonadherence with Glaucoma Therapy.
    Wolfram C; Stahlberg E; Pfeiffer N
    J Ocul Pharmacol Ther; 2019 May; 35(4):223-228. PubMed ID: 30897019
    [No Abstract]   [Full Text] [Related]  

  • 14. Ocular Surface Disease in the Glaucoma Patient.
    Banitt M; Jung H
    Int Ophthalmol Clin; 2018; 58(3):23-33. PubMed ID: 29870408
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of common ophthalmic preservatives on ocular health.
    Noecker R
    Adv Ther; 2001; 18(5):205-15. PubMed ID: 11783457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tear Film, Conjunctival and Corneal Modifications Induced by Glaucoma Treatment.
    Roberti G; Tanga L; Manni G; Riva I; Verticchio AC; Berardo F; Carnevale C; Oddone F
    Curr Med Chem; 2019; 26(22):4253-4261. PubMed ID: 31099319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benzalkonium chloride in glaucoma medications.
    Noecker R; Miller KV
    Ocul Surf; 2011 Jul; 9(3):159-62. PubMed ID: 21791190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unilateral drug-induced ocular pseudopemphigoid.
    Gibran SK
    Eye (Lond); 2004 Dec; 18(12):1270. PubMed ID: 15044940
    [No Abstract]   [Full Text] [Related]  

  • 19. Topical glaucoma medications - Clinical implications for the ocular surface.
    Fineide F; Lagali N; Adil MY; Arita R; Kolko M; Vehof J; Utheim TP
    Ocul Surf; 2022 Oct; 26():19-49. PubMed ID: 35921942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detrimental effect of preservatives in eyedrops: implications for the treatment of glaucoma.
    Baudouin C
    Acta Ophthalmol; 2008 Nov; 86(7):716-26. PubMed ID: 18537937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.